BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37423815)

  • 1. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
    Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
    Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
    Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
    Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
    Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
    Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
    J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
    Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
    Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
    Lenfant L; Leon P; Cancel-Tassin G; Audouin M; Staerman F; Rouprêt M; Cussenot O
    Urol Oncol; 2020 Aug; 38(8):661-670. PubMed ID: 32409202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Zhang Y
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
    Shoskes DA; Barazani Y; Fareed K; Sabanegh E
    Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis.
    Boyle P; Koechlin A; Bota M; d'Onofrio A; Zaridze DG; Perrin P; Fitzpatrick J; Burnett AL; Boniol M
    BJU Int; 2016 Nov; 118(5):731-741. PubMed ID: 26779889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
    Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMAS position statement: Testosterone replacement therapy in older men.
    Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
    Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
    Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous Testosterone Replacement Therapy Is Associated with Increased Risk for Vascular Graft Infections Among Hypogonadal Men.
    Longwolf KJ; Johnson CE; Horns JJ; Hotaling JM; Brooke BS
    Ann Vasc Surg; 2023 Nov; 97():113-120. PubMed ID: 37453467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.